Abstract: Rheumatic immune diseases usually involve multiple organs. Pregnancy and childbirth may aggravate the condition and endanger the life of patients. With the development of modern medicine and multi-disciplinary cooperation, rheumatic immune disease is no longer a contraindication for pregnancy. Meanwhile, breastfeeding is beneficial to both maternal and child health and family economy. The medication safety of patients with rheumatic immune disease should consider not only the disease itself, but also the safety of mothers and infants before and during pregnancy, as well as the development and health of breast-feeding children. The commonly used anti-rheumatic immune drugs include glucocorticoids, hydroxychloroquine, non-steroidal anti-inflammatory drugs, immune-suppressants and biological agents. Different drugs have different applications in pregnancy and lactation. Therefore, more attention should be paid to the safety of anti-rheumatic immune drugs in women of childbearing age. To have a good grasp of the influence of the medication on offspring and the safe dosage range is helpful to provide more theoretical basis for the guidance of drug use during pregnancy and lactation.

Key words: Connective tissue diseases；, Pregn；, Breast feeding；, Fetal development；, Drug therapy；, Risk assessment